Zinlirvimab (10-1074-LS): A Comprehensive Analysis of a Long-Acting Broadly Neutralizing Antibody for HIV Treatment and Prevention

Section 1: Executive Summary & Overview of Zinlirvimab (10-1074-LS)

Introduction and Nomenclature

10-1074-LS is an investigational human monoclonal antibody being developed for the treatment and prevention of Human Immunodeficiency Virus Type 1 (HIV-1) infection. It represents a significant advancement in the field of passive immunotherapy, belonging to a class of molecules known as broadly neutralizing antibodies (bNAbs).[1] Originally discovered by researchers at The Rockefeller University, the antibody and its long-acting variant have been licensed for clinical development by Gilead Sciences, Inc..[3] In this context, it is identified by several names: the research designation 10-1074-LS, the generic name zinlirvimab, and the Gilead development code GS-2872.[2] The "-LS" suffix denotes a critical modification engineered to extend its biological half-life, a feature central to its therapeutic strategy.

Classification and Therapeutic Rationale